Rifampicin for non-tuberculous infections? 1985

R N Grüneberg, and A M Emmerson, and A W Cremer

Large populations of rifampicin-sensitive strains of Mycobacterium tuberculosis have been exposed in vitro to changing concentrations of rifampicin (RIF) in line with changes in the blood level of the drug observed during treatment, and to much lower concentrations. Experiments in which the organism was exposed to either 7 or 14 days of cyclically-changing rifampicin concentrations have resulted in the elimination of the M. tuberculosis test strains without the emergence of RIF resistance. The significance of these laboratory findings is discussed in relation to the debate as to whether rifampicin should be used in short courses for the treatment of non-tuberculous infections or whether it should be withheld for fear of inadvertently generating rifampicin-resistant strains of tubercle bacilli. It is argued that the evidence for withholding rifampicin from use in short courses against non-tuberculous infections is slight.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001424 Bacterial Infections Infections by bacteria, general or unspecified. Bacterial Disease,Bacterial Infection,Infection, Bacterial,Infections, Bacterial,Bacterial Diseases
D012293 Rifampin A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) Rifampicin,Benemycin,Rifadin,Rimactan,Rimactane,Tubocin
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

R N Grüneberg, and A M Emmerson, and A W Cremer
July 1984, British medical journal (Clinical research ed.),
R N Grüneberg, and A M Emmerson, and A W Cremer
August 1984, British medical journal (Clinical research ed.),
R N Grüneberg, and A M Emmerson, and A W Cremer
November 1989, The Journal of antimicrobial chemotherapy,
R N Grüneberg, and A M Emmerson, and A W Cremer
December 1988, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
R N Grüneberg, and A M Emmerson, and A W Cremer
January 1982, Chemotherapy,
R N Grüneberg, and A M Emmerson, and A W Cremer
March 2012, Revue des maladies respiratoires,
R N Grüneberg, and A M Emmerson, and A W Cremer
May 2008, La Revue de medecine interne,
R N Grüneberg, and A M Emmerson, and A W Cremer
November 1949, The Antiseptic,
R N Grüneberg, and A M Emmerson, and A W Cremer
January 2006, Scandinavian journal of infectious diseases,
R N Grüneberg, and A M Emmerson, and A W Cremer
November 2000, Age and ageing,
Copied contents to your clipboard!